The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Haematologica. 2019 Jul;104(7):e307-e309. doi: 10.3324/haematol.2018.214759. Epub 2019 Jan 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Cell Proliferation / drug effects*
  • Drug Synergism*
  • Humans
  • Hydrazines / administration & dosage
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, B-Cell / pathology
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / pathology
  • Niacinamide / administration & dosage
  • Niacinamide / analogs & derivatives
  • Piperidines / administration & dosage
  • Pyrazoles / administration & dosage
  • Pyrimidines / administration & dosage
  • Sulfonamides / administration & dosage
  • Triazoles / administration & dosage
  • Tumor Cells, Cultured

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Hydrazines
  • N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • Triazoles
  • ibrutinib
  • Niacinamide
  • selinexor
  • zanubrutinib
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human
  • Adenine
  • venetoclax